Skip to content
Disclosery

BIOS Capital Management, LP

Follow

13F filer, CIK 1813845, Fort Worth, TX

BIOS Capital Management, LP reported $88,912,596 across 6 holdings for the quarter ended 2025-09-30, in a 13F-HR filed 2025-11-12.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001104659-25-110482

Period
2025-09-30
Reported value
$88.9M
Holdings
6
Top 10 weight
100%
New
0
Sold out
0

Part of the filer group BIOS Capital Management, LP

How groups are built

Largest buys vs the previous quarter

SecurityShares changeApprox. value
ACTUadded+84,917$568K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
LTRNreduced-60,237-$262K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2025

Share positions as resolved from 13F-HR 0001104659-25-110482, largest first. % of portfolio is the value over $88,912,596, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
ACTUACTUATE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 9,893,651 shares; 2025Q1: 9,893,651 shares; 2025Q2: 9,965,079 shares; 2025Q3: 10,049,996 shares 10,049,996$67.2M75.62%+84,917Timeline
CGTXCOGNITION THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 6,000,000 shares; 2025Q1: 6,000,000 shares; 2025Q2: 6,000,000 shares; 2025Q3: 6,000,000 shares 6,000,000$8.1M9.11%0Timeline
IRDOPUS GENETICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 995,249 shares; 2025Q1: 995,249 shares; 2025Q2: 3,683,429 shares; 2025Q3: 3,683,429 shares 3,683,429$6.59M7.42%0Timeline
LTRNLANTERN PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 1,207,709 shares; 2025Q1: 1,207,709 shares; 2025Q2: 1,075,952 shares; 2025Q3: 1,015,715 shares 1,015,715$4.42M4.97%-60,237Timeline
RNTXREIN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 1,690,751 shares; 2025Q1: 1,690,751 shares; 2025Q2: 1,690,751 shares; 2025Q3: 1,690,751 shares 1,690,751$1.94M2.19%0Timeline
IN8BIO INCIN8BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 8,600,001 shares; 2025Q1: 8,600,001 shares; 2025Q2: 286,664 shares; 2025Q3: 286,664 shares 286,664$622K0.7%0

How Q3 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001104659-25-110482 base2025-11-12acceptance time not in the bulk data set